Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin

Stopped early · Phase 2

Conditions studied: Pancreatic Neoplasm, Pituitary Neoplasm, Nelson Syndrome, Ectopic ACTH Syndrome

In brief

This study will assess the effectiveness and safety of pasireotide long-acting release in patients who have rare tumors of neuroendocrine origin.

Key facts

Study ID

NCT00958841

Run by

Novartis Pharmaceuticals

People needed

118

Starts

2009-09-01

Expected to finish

2015-06-01

Last updated by the study team

2016-07-26

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male and Female Patients at least 18 years old
• Patient who have rare tumors of neuroendocrine origin, such as tumors of the:
• pancreas
• pituitary glands
• Nelson syndrome
• ectopic-ACTH secreting tumor
• Patients who have failed standard of care treatment or for whom no standard of care treatment exist
• Signed Informed Consent

You may not qualify if…

• Patients with active gallbladder disease
• Patients with any ongoing or planned anti-neoplastic or interferon therapy
• Poorly controlled diabetes mellitus
• Female patients who are pregnant or lactating, or are of childbearing potential and not practicing a medically acceptable method of birth control
• Other protocol-defined inclusion/exclusion criteria may apply.

Where it is running

• Cedars Sinai Medical Center Cedars Sinai 4 — Los Angeles, California, United States
• Cedars Sinai Medical Center The Pituitary Center (3) — Los Angeles, California, United States
• Stanford University Medical Center SC — Stanford, California, United States
• Dana Farber Cancer Institute Deptof DanaFarberCancerInst(5) — Boston, Massachusetts, United States
• Mount Sinai School of Medicine Study Coordinator — New York, New York, United States
• Swedish Medical Center Dept.ofSwedishMedicalCtr.(2) — Seattle, Washington, United States
• Novartis Investigative Site — Buenos Aires, Buenos Aires, Argentina
• Novartis Investigative Site — Westmead, New South Wales, Australia
• Novartis Investigative Site — Fitzroy, Victoria, Australia
• Novartis Investigative Site — Fortaleza, Ceará, Brazil
• Novartis Investigative Site — Belo Horizonte, Minas Gerais, Brazil
• Novartis Investigative Site — Botucatu, São Paulo, Brazil
• Novartis Investigative Site — Halifax, Nova Scotia, Canada
• Novartis Investigative Site — Montreal, Quebec, Canada
• Novartis Investigative Site — Strasbourg, France, France
• Novartis Investigative Site — Angers, France
• Novartis Investigative Site — Bron, France
• Novartis Investigative Site — Le Kremlin-Bicêtre, France
• Novartis Investigative Site — Lille, France
• Novartis Investigative Site — Marseille, France
• Novartis Investigative Site — Pessac, France
• Novartis Investigative Site — Reims, France
• Novartis Investigative Site — Berlin, Germany
• Novartis Investigative Site — Berlin, Germany
• Novartis Investigative Site — Erlangen, Germany

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.